
CSPC Pharma Group is a Chinese pharmaceutical manufacturer selling finished drugs and bulk drug ingredients.
cspc.com.hkCrawled Nov 16, 2026
AstraZeneca and CSPC are establishing a joint venture to operate a biologics manufacturing facility in Shijiazhuang, China. CSPC holds a 51% stake and will provide its AI-driven good manufacturing practice system, while AstraZeneca contributes global quality and supply-chain expertise. The partnership combines CSPC’s technology with AstraZeneca’s operational experience to support biologics production.
Aug 2026Fierce PharmaNews article
CSPC Pharmaceutical Group receives China NMPA approval for its fast-dissolving albumin-bound paclitaxel injection (II) for metastatic breast cancer. The drug demonstrates a **27% reduction in disease progression or death risk** and a **33% reduction in death risk** in Phase III trials. This marks the first fast-dissolving formulation of albumin-bound paclitaxel globally.
Jun 2026MedPath TrialNews article
AstraZeneca pays **$1.2 billion upfront** to **CSPC Pharmaceuticals** for global ex-China rights to its obesity drug pipeline, including **SYH2082**, a once-monthly injectable GLP-1/GIP receptor agonist entering **Phase 1 trials**. The portfolio spans eight programs targeting weight management. AstraZeneca previously exited China’s obesity market and now re-engages via this licensing deal.
Jan 2026Fierce BiotechNews article
AstraZeneca invests **$110 million upfront** in CSPC Pharmaceutical to develop **oral drugs for chronic diseases** using its AI-driven platform. The deal includes up to **$1.62 billion in development milestones** and **$3.6 billion in sales milestones**, totaling a **$5.3 billion** potential agreement. CSPC leverages its AI technology to accelerate drug discovery for unmet medical needs.
Jun 2025Fierce BiotechNews article